Market Overview

FDA Approves First Ebola Vaccine

Share:
FDA Approves First Ebola Vaccine

American pharmaceutical company Merck & Co., Inc. (NYSE: MRK) received FDA approval for its Ebola vaccine Ervebo on Thursday, according to Reuters.

What Happened

The FDA said had approved Merck’s Ebola vaccine, Ervebo, making it the first FDA-approved vaccine against the lethal virus.

The World Health Organization and the Democratic Republic of the Congo earlier used the Ervebo vaccine, mainly during the period between 2014 and 2016, to reduce Ebola disease outbreaks in some West African countries.

The injectable Ebola vaccine, Ervebo, will help to prevent EVD caused by Zaire ebolavirus in patients aged 18 years and older, said the FDA in a statement.

Why It Matters

A recent Ebola outbreak, which started in August 2018, killed more than 2,100 people, including over 160 health workers since the middle of last year.

European drug regulators have already approved the vaccine in October 2019, a decision that the WHO appreciated at the time.

“This vaccine has already saved many lives in the current Ebola outbreak, and the decision by European regulators will help it to eventually save many more,” said Tedros Adhanom Ghebreyesus, director-general of WHO, at the time.

 

Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: Ebola Virus Disease Merck & Co. Inc. World Health OrganizationNews Health Care Global Media General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com